BioLife Solutions’ (BLFS) “Buy” Rating Reaffirmed at Benchmark

Benchmark reiterated their buy rating on shares of BioLife Solutions (NASDAQ:BLFS) in a report published on Thursday,Benzinga reports. Benchmark currently has a $30.00 price target on the medical equipment provider’s stock.

BLFS has been the topic of several other reports. KeyCorp lifted their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. HC Wainwright decreased their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. TD Cowen raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Craig Hallum lifted their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.00.

BioLife Solutions Trading Up 4.9 %

Shares of BLFS opened at $27.39 on Thursday. BioLife Solutions has a twelve month low of $14.50 and a twelve month high of $28.88. The firm has a market capitalization of $1.27 billion, a P/E ratio of -25.84 and a beta of 1.91. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock’s fifty day simple moving average is $24.96 and its 200 day simple moving average is $23.72.

Insider Activity

In other BioLife Solutions news, EVP Aby J. Mathew sold 17,604 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the transaction, the executive vice president now owns 284,442 shares in the company, valued at $5,703,062.10. The trade was a 5.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 64,259 shares of company stock worth $1,424,708. 2.20% of the stock is currently owned by company insiders.

Institutional Trading of BioLife Solutions

Hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. boosted its holdings in BioLife Solutions by 4.7% in the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock valued at $4,776,000 after purchasing an additional 8,580 shares during the last quarter. Barclays PLC boosted its stake in shares of BioLife Solutions by 20.1% during the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after buying an additional 10,803 shares during the last quarter. Geode Capital Management LLC grew its position in shares of BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after buying an additional 18,473 shares in the last quarter. State Street Corp grew its position in shares of BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after buying an additional 95,788 shares in the last quarter. Finally, Stifel Financial Corp increased its stake in shares of BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after buying an additional 670 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.